Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Free Cash Flow (2016 - 2025)

Anaptysbio's Free Cash Flow history spans 10 years, with the latest figure at $98.1 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 247.31% year-over-year to $98.1 million; the TTM value through Dec 2025 reached $19.7 million, up 114.55%, while the annual FY2025 figure was $19.7 million, 114.55% up from the prior year.
  • Free Cash Flow reached $98.1 million in Q4 2025 per ANAB's latest filing, up from -$27.4 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $98.1 million in Q4 2025 to a low of -$66.6 million in Q4 2024.
  • Average Free Cash Flow over 5 years is -$17.9 million, with a median of -$23.9 million recorded in 2021.
  • Peak YoY movement for Free Cash Flow: plummeted 347.08% in 2022, then surged 247.31% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$26.7 million in 2021, then surged by 60.02% to -$10.7 million in 2022, then plummeted by 224.97% to -$34.6 million in 2023, then plummeted by 92.28% to -$66.6 million in 2024, then soared by 247.31% to $98.1 million in 2025.
  • Per Business Quant, the three most recent readings for ANAB's Free Cash Flow are $98.1 million (Q4 2025), -$27.4 million (Q3 2025), and -$40.3 million (Q2 2025).